ÿþ<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"> <html> <head> <meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1"> <title>EASL 2011 - Poster Presentations</title> <link rel="stylesheet" type="text/css" href="style.css"> </head> <body> <table width="750" align="center" border="0" cellspacing="0" cellpadding="0" class="MainTable"> <tr> <td><img src="http://www2.kenes.com/liver-congress/PublishingImages/top_ei.jpg" width="760" height="129" /></td> </tr> <tr> <td class="content"><p><b>Abstracts on line are sponsored by</b><br /> <img src="../logo_janssen.jpg" /></p><h1>Poster Presentations</h1> <P><b><u> 31 March - 2, April, 2011</u></b></P><p align=right><em>Poster Board Number</em></p><H2>Category 15: Late-Breakers:<br /></H2><table><tr> <td><a href='Abstract5.htm'><B>IL28B POLYMORPHISMS LINKED TO POOR RESPONSE TO TREATMENT ARE ASSOCIATED WITH LOW NECROINFLAMMATORY ACTIVITY AND SLOW FIBROSIS PROGRESSION IN HCV GENOTYPE NON-1-INFECTED PATIENTS</B></a> </em><br> <b>P.-Y. Bochud</b><sup>1</sup>*, S. Bibert<sup>2</sup>, Z. Kutalik<sup>3,4</sup>, N. Goossens<sup>5</sup>, B. Müllhaupt<sup>6</sup>, T. Gerlach<sup>7</sup>, M. Heim<sup>8</sup>, D. Moradpour<sup>9</sup>, A. Cerny<sup>10</sup>, R. Malinverni<sup>11</sup>, J.-F. Dufour<sup>12</sup>, F. Negro<sup>5</sup>, The Swiss Hepatitis C Cohort Study Group<br> <em><sup>1</sup>Infectious Diseases, <sup>2</sup>University Hospital of Lausanne, <sup>3</sup>University of Lausanne, <sup>4</sup>Swiss Institute of Bioinformatics, Lausanne, <sup>5</sup>University Hospital of Geneva, Geneva, <sup>6</sup>University Hospital of Zurich, Zurich, <sup>7</sup>Canton Hospital, St Gallen, <sup>8</sup>University Hospital, Basel, <sup>9</sup>University Hospital, Lausanne, <sup>10</sup>Clinica Moncucco, Lugano, <sup>11</sup>Hôpital Pourtalès, Neuchatel, <sup>12</sup>University Hospital, Berne, Switzerland. *pierre-yves.bochud@chuv.ch</em></td><td valign=top><em>1361 </td></tr> <tr> <td><a href='Abstract10.htm'><B>THE AVAILABILITY OF DIRECT ACTING ANTIVIRALS (DAA) IN 2012: A FRENCH MODEL-BASED ANALYSIS OF THE INCREASED NUMBER OF PATIENTS TREATED FOR CHRONIC HCV INFECTION</B></a> </em><br> <b>S. Deuffic-Burban</b><sup>1,2</sup>*, P. Mathurin<sup>3,4</sup>, S. Pol<sup>5</sup>, C. Larsen<sup>6</sup>, F. Roudot-Thoraval<sup>7</sup>, J.-C. Desenclos<sup>6</sup>, D. Dhumeaux<sup>8</sup>, Y. Yazdanpanah<sup>1,2,9</sup><br> <em><sup>1</sup>ATIP-AVENIR, Inserm U995, Université Lille Nord de France, Loos, <sup>2</sup>EA2694, Université Lille Nord de France, <sup>3</sup>Service des Maladies de l'Appareil Digestif et de la Nutrition, Hôpital Huriez, CHRU Lille, <sup>4</sup>Inserm U995, Université Lille Nord de France, Lille, <sup>5</sup>Groupe Hospitalier Cochin Hôtel Dieu, Unité d'Hépatologie, Université Paris Descartes et Inserm U-1016, Paris, <sup>6</sup>Département des maladies infectieuses, Institut de Veille Sanitaire, Saint Maurice, <sup>7</sup>Service Santé Publique, Hôpital Henri Mondor, <sup>8</sup>Inserm U955, Physiopathologie et thérapeutique des hépatites virales chroniques, Hôpital Henri-Mondor, Créteil, <sup>9</sup>Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, Tourcoing, France. *sylvie.burban@neuf.fr</em></td><td valign=top><em>1362 </td></tr> <tr> <td><a href='Abstract3.htm'><B><B><B><B>VX-222 WITH TVR ALONE OR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAïVE PATIENTS WITH CHRONIC HEPATITIS C: ZENITH STUDY INTERIM RESULTS</B> </B></B></B></a> </em><br> <b>A.M. Di Bisceglie</b><sup>1</sup>*, D.R. Nelson<sup>2</sup>, E. Gane<sup>3</sup>, K. Alves<sup>4</sup>, M.J. Koziel<sup>4</sup>, C. De Souza<sup>4</sup>, T.L. Kieffer<sup>4</sup>, S. George<sup>4</sup>, R.S. Kauffman<sup>4</sup>, I.M. Jacobson<sup>5</sup>, M.S. Sulkowski<sup>6</sup>, ZENITH Study Team<br> <em><sup>1</sup>St Louis University School of Medicine, St. Louis, MO, <sup>2</sup>University of Florida College of Medicine, Gainesville, FL, USA, <sup>3</sup>Auckland City Hospital, Auckland, New Zealand, <sup>4</sup>Vertex Pharmaceuticals Incorporated, Cambridge, MA, <sup>5</sup>Weill Cornell Medical College, New York, NY, <sup>6</sup>Johns Hopkins University, Baltimore, MD, USA. *dibiscam@slu.edu</em></td><td valign=top><em>1363 </td></tr> <tr> <td><a href='Abstract11.htm'><B><B>DEEP SEQUENCING REVEALS ACCUMULATION OF VIRAL VARIANTS IN HCV GENOTYPE 1 INFECTED PATIENTS DURING RIBAVIRIN MONOTHERAPY</B></B></a> </em><br> <b>J. Dietz</b><sup>1</sup>*, U. Mihm<sup>1</sup>, S.-E. Schelhorn<sup>2</sup>, D. Fitting<sup>1</sup>, S. Susser<sup>1</sup>, T. Lengauer<sup>2</sup>, S. Zeuzem<sup>1</sup>, E. Herrmann<sup>1</sup>, C. Sarrazin<sup>1</sup><br> <em><sup>1</sup>Medizinische Klinik 1, Klinikum der J. W. Goethe-Universität, Frankfurt/Main, <sup>2</sup>Max-Planck-Institut für Informatik, Saarbrücken, Germany. *julia.dietz@em.uni-frankfurt.de</em></td><td valign=top><em>1364 </td></tr> <tr> <td><a href='Abstract15.htm'><B><B>ACUTE KIDNEY INJURY NETWORK (AKIN) CRITERIA FOR ACUTE RENAL FAILURE PREDICTS OUTCOME IN HOSPITALIZED CIRRHOTIC PATIENTS. A PROSPECTIVE STUDY</B></B></a> </em><br> <b>C. Fagundes</b><sup>1,2,3</sup>*, M. Guevara<sup>1,2,3</sup>, E. García-López<sup>1,2,3</sup>, G.H. Pereira<sup>1,2,3</sup>, E. Solà<sup>1,2,3</sup>, E. Rodríguez<sup>1,2,3</sup>, M. Pavesi<sup>1,2,3</sup>, V. Arroyo<sup>1,2,3</sup>, P. Ginès<sup>1,2,3</sup><br> <em><sup>1</sup>Liver Unit, University of Barcelona, <sup>2</sup>IDIBAPS, <sup>3</sup>CIBER de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain. *cgoncalv@clinic.ub.es</em></td><td valign=top><em>1365 </td></tr> <tr> <td><a href='Abstract4.htm'><B><B>HIGH SUSTAINED VIROLOGIC RESPONSE (SVR) AMONG GENOTYPE 1 PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN RE-TREATED WITH BOCEPREVIR (BOC) PLUS PEGINTERFERON ALFA-2A/RIBAVIRIN</B></B></a> </em><br> <b>S. Flamm</b><sup>1</sup>*, E. Lawitz<sup>2</sup>, I. Jacobson<sup>3</sup>, R. Rubin<sup>4</sup>, M. Bourliere<sup>5</sup>, C. Hezode<sup>6</sup>, J. Vierling<sup>7</sup>, C. Niederau<sup>8</sup>, M. Sherman<sup>9</sup>, V. Goteti<sup>10</sup>, R. Vilchez<sup>10</sup>, C. Brass<sup>10</sup>, J. Albrecht<sup>10</sup>, F. Poordad<sup>11</sup><br> <em><sup>1</sup>Northwestern Feinberg School of Medicine, Chicago, IL, <sup>2</sup>Alamo Medical Research, SanAntonio, TX, <sup>3</sup>Weill Cornell Medical College, New York, NY, <sup>4</sup>Liver Center of Atlanta, Atlanta, GA, USA, <sup>5</sup>Fondation Hopital Saint Joseph, Marseille, <sup>6</sup>A.P.H. Paris, Hopital Henri Mondor, Creteil Cedex, France, <sup>7</sup>Baylor College of Medicine, Houston, TX, USA, <sup>8</sup>St. Josef-Hospital Oberhausen, Oberhausen, Germany, <sup>9</sup>Toronto General Hospital, Toronto, ON, Canada, <sup>10</sup>Merck Sharp & Dohme Corp., Whitehouse Station, NJ, <sup>11</sup>Cedars-Sinai Medical Center, Los Angeles, CA, USA. *s-flamm@northwestern.edu</em></td><td valign=top><em>1366 </td></tr> <tr> <td><a href='Abstract12.htm'><B>RELAPSE AFTER ANALOGUES TREATMENT DISCONTINUATION IS NOT PREVENTED BY DNA VACCINATION IN CHRONIC HEPATITIS B (ANRS HB 02 VAC-ADN)</B></a> </em><br> <b>H. Fontaine</b><sup>1,2</sup>*, C. Chazallon<sup>3</sup>, M. Mancini-Bourgine<sup>4,5</sup>, P. Lebray<sup>6</sup>, C. Buffet<sup>7</sup>, S. Kahi<sup>8</sup>, O. Godon<sup>9</sup>, J.-F. Meritet<sup>10</sup>, Y. Saïdi<sup>11</sup>, M.-L. Michel<sup>12,13</sup>, D. Scott-Algara<sup>14</sup>, J.-P. Aboulker<sup>15</sup>, S. Pol<sup>16,17,18</sup>, ANRS HB 02 VAC-ADN Study Group<br> <em><sup>1</sup>Unité d'Hepatologie, APHP, Groupe Hospitalier Cochin Saint-Vincent de Paul, <sup>2</sup>CNRS (UMR 8104), Institut Cochin, Université Paris Descartes (UMR S1016), Paris, <sup>3</sup>SC10, INSERM, Villejuif, <sup>4</sup>Laboratoire de pathogenèse des virus de l'hépatite B, Institut Pasteur, <sup>5</sup>U845, Institut national de la santé et de la recherche médicale, <sup>6</sup>Hepatology Unit, Hôpital de la Pitié-Salpétrière, Paris, <sup>7</sup>Hepatology Unit, Hôpital du Kremlin-Bicêtre, Le Kremlin-Bicêtre, <sup>8</sup>SC10, InNSERM, Villejuif, <sup>9</sup>laboratoire de pathogenèse des virus de l'hépatite B, Institut Pasteur, <sup>10</sup>Virology Unit, APHP, Groupe Hospitalier Cochin Saint-Vincent de Paul, Paris, <sup>11</sup>SC10, Inserm, Villejuif, <sup>12</sup>Laboratoire de pathogénèse des virus de l'hépatite B, Institut Pasteur, <sup>13</sup>U845, Institut de la Santé et de la Recherche Biomédicale, <sup>14</sup>Unité de régulation des infections rétrovirales, Institut Pasteur, <sup>15</sup>SC10, Inserm, <sup>16</sup>Unité d'Hépatologie, Groupe Hospitalier Cochin Saint-Vincent de Paul, <sup>17</sup>UMR S1016, Institut Cochin, Université Paris Descartes, <sup>18</sup>U1016, Inserm, Paris, France. *helene.fontaine@cch.aphp.fr</em></td><td valign=top><em>1367 </td></tr> <tr> <td><a href='Abstract1.htm'><B>WESTERN TRIAL COMPARING PERCUTANEOUS RADIOFREQUENCY OF BOTH HEPATOCELLULAR CARCINOMA AND THE PORTAL VENOUS TUMOR THROMBUS PLUS SORAFENIB WITH SORAFENIB ALONE</B></a> </em><br> <b>A. Giorgio</b>*, N. Farella, A. di Sarno, U. Scognamiglio, G. de Stefano, A. de Rogatis, E. Trapenese, V. Giorgio<br> <em>Infectious Disease and Interventional Ultrasound Unit, Naples, Italy. *assanui1@virgilio.it</em></td><td valign=top><em>1368 </td></tr> <tr> <td><a href='Abstract7.htm'><B><B><B>TELAPREVIR SUBSTANTIALLY IMPROVED SVR RATES ACROSS ALL IL28B GENOTYPES IN THE ADVANCE TRIAL</B> </B></B></a> </em><br> <b>I.M. Jacobson</b><sup>1</sup>*, I. Catlett<sup>2</sup>, P. Marcellin<sup>3</sup>, N.H. Bzowej<sup>4</sup>, A.J. Muir<sup>5</sup>, N. Adda<sup>2</sup>, L. Bengtsson<sup>2</sup>, S. George<sup>2</sup>, S. Seepersaud<sup>2</sup>, R. Ramachandran<sup>2</sup>, K. Sussky<sup>2</sup>, R.S. Kauffman<sup>2</sup>, M. Botfield<sup>2</sup><br> <em><sup>1</sup>Weill Cornell Medical College, New York, NY, <sup>2</sup>Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA, <sup>3</sup>Hôpital Beaujon, Clichy, France, <sup>4</sup>California Pacific Medical Center, San Francisco, CA, <sup>5</sup>Duke University Medical Center, Durham, NC, USA. *imj2001@med.cornell.edu</em></td><td valign=top><em>1369 </td></tr> <tr> <td><a href='Abstract8.htm'><B><B>ONCE DAILY DUAL-NUCLEOTIDE COMBINATION OF PSI-938 AND PSI-7977 PROVIDES 94% HCV RNA < LOD AT DAY 14: FIRST PURINE/PYRIMIDINE CLINICAL COMBINATION DATA (THE NUCLEAR STUDY)</B></B></a> </em><br> <b>E. Lawitz</b><sup>1</sup>*, M. Rodriguez-Torres<sup>2</sup>, J. Denning<sup>3</sup>, M. Cornpropst<sup>3</sup>, D. Clemons<sup>3</sup>, L. Mcnair<sup>3</sup>, M.M. Berrey<sup>3</sup>, W. Symonds<sup>3</sup><br> <em><sup>1</sup>Alamo Medical Resarch, San Antonio, TX, <sup>2</sup>Fundacion de Investigacion De Diego, San Juan, PR, <sup>3</sup>Pharmasset, Inc., Princeton, NJ, USA. *lawitz@alamomedicalresearch.com</em></td><td valign=top><em>1370 </td></tr> <tr> <td><a href='Abstract16.htm'><B><B>PROGRESS TOWARD THE CLINICAL APPLICATION OF AUTOLOGOUS INDUCED PLURIPOTENT STEM CELLS AND GENE REPAIR THERAPY FOR TREATMENT OF FAMILIAL HYPERCHOLESTEROLEMIA</B></B></a> </em><br> A. Bosman<sup>1</sup>, B.E. Wildhaber<sup>2</sup>, J. Birraux<sup>2</sup>, C. Jond<sup>2</sup>, M. Jaconi<sup>1</sup>, <b>O. Menzel</b><sup>2</sup>*<br> <em><sup>1</sup>Dpt. of Pathology and Immunology, <sup>2</sup>Research Laboratory of Pediatric Surgery (Dpt. of Pathology and Immunology), University of Geneva Medical School (CMU), Geneva, Switzerland. *olivier.menzel@unige.ch</em></td><td valign=top><em>1371 </td></tr> <tr> <td><a href='Abstract9.htm'><B><B>ONCE DAILY PSI-7977 PLUS PEG-IFN/RBV IN HCV GT1: 98% RAPID VIROLOGIC RESPONSE, COMPLETE EARLY VIROLOGIC RESPONSE: THE PROTON STUDY</B></B></a> </em><br> <b>D.R. Nelson</b><sup>1</sup>*, J. Lalezari<sup>2</sup>, E. Lawitz<sup>3</sup>, T. Hassanein<sup>4</sup>, K. Kowdley<sup>5</sup>, F. Poordad<sup>6</sup>, A. Sheikh<sup>7</sup>, N. Afdhal<sup>8</sup>, D. Bernstein<sup>9</sup>, E. Dejesus<sup>10</sup>, B. Freilich<sup>11</sup>, D. Dieterich<sup>12</sup>, I. Jacobson<sup>13</sup>, D. Jensen<sup>14</sup>, G.A. Abrams<sup>15</sup>, J. Darling<sup>16</sup>, M. Rodriguez-Torres<sup>17</sup>, R. Reddy<sup>18</sup>, M. Sulkowski<sup>19</sup>, N. Bzowej<sup>20</sup>, M. Demicco<sup>21</sup>, J. Strohecker<sup>22</sup>, R. Hyland<sup>23</sup>, M. Mader<sup>23</sup>, E. Albanis<sup>23</sup>, W.T. Symonds<sup>23</sup>, M.M. Berrey<sup>23</sup><br> <em><sup>1</sup>University of Florida, Gainesville, FL, <sup>2</sup>Quest Clinical Research, San Francisco, CA, <sup>3</sup>Alamo Medical Research, Ltd, San Antonio, TX, <sup>4</sup>University of California, San Diego, Coronado, CA, <sup>5</sup>Virginia Mason Medical Center, Seattle, WA, <sup>6</sup>Cedars-Sinai Medical Center, Los Angeles, CA, <sup>7</sup>GI Specialists of Georgia, Marietta, GA, <sup>8</sup>Beth Israel Deaconess Medical Center,Harvard Medical School, Boston, MA, <sup>9</sup>Digestive Diseases Institute of the Division of Gastroenterology, Hepatology, and Nutrition, Manhasset, NY, <sup>10</sup>Orlando Immunology Center, Orlando, FL, <sup>11</sup>Kansas City Gastroenterology & Hepatology, LLCG, Kansas City, KS, <sup>12</sup>Mount Sinai School of Medicine, New York, <sup>13</sup>Cornell University, New York, NY, <sup>14</sup>University of Chicago Hospital, Chicago, IL, <sup>15</sup>Alabama Liver and Digestive Specialists, Montgomery, AL, <sup>16</sup>University of North Carolina at Chapel Hill, Chapel Hill, NC, <sup>17</sup>Fundacion de Investigacion De Diego, Santurce, PR, <sup>18</sup>University of Pennsylvania Health System, Philadelphia, PA, <sup>19</sup>Johns Hopkins University School of Medicine, Lutherville, MD, <sup>20</sup>California Pacific Medical Center, San Francisco, <sup>21</sup>Advanced Clinical Research Institute, Anaheim, CA, <sup>22</sup>Columbia Gastroenterology, Columbia, SC, <sup>23</sup>Pharmasset, Inc, Princeton, NJ, USA. *david.nelson@medicine.ufl.edu</em></td><td valign=top><em>1372 </td></tr> <tr> <td><a href='Abstract2.htm'><B><B>FIRST REPORT OF SVR12 FOR A NS5A </B><B>REPLICATION COMPLEX INHIBITOR, BMS-790052 IN COMBINATION WITH</B> <B>PEG-IFN±-2A AND RBV: PHASE 2A TRIAL IN TREATMENT-NAIVE HCV-GENOTYPE 1 SUBJECTS</B></B></a> </em><br> <b>S. Pol</b><sup>1</sup>*, R.H. Ghalib<sup>2</sup>, V.K. Rustgi<sup>3</sup>, C. Martorell<sup>4</sup>, G.T. Everson<sup>5</sup>, H.A. Tatum<sup>6</sup>, C. Hezode<sup>7</sup>, J.K. Lim<sup>8</sup>, J.-P. Bronowicki<sup>9</sup>, G.A. Abrams<sup>10</sup>, N. Brau<sup>11</sup>, D.W. Morris<sup>12</sup>, P. Thuluvath<sup>13</sup>, R. Reindollar<sup>14</sup>, P.D. Yin<sup>15</sup>, U. Diva<sup>15</sup>, R. Hindes<sup>15</sup>, F. McPhee<sup>15</sup>, M. Gao<sup>15</sup>, A. Thiry<sup>15</sup>, S. Schnittman<sup>15</sup>, E.A. Hughes<sup>15</sup><br> <em><sup>1</sup>Hôpital Cochin, Paris, France, <sup>2</sup>Liver Institute at Methodist Health System, Dallas, TX, <sup>3</sup>Metropolitan Research, Fairfax, VA, <sup>4</sup>The Research Institute, Springfield, MA, <sup>5</sup>University of Colorado, Aurora, CO, <sup>6</sup>Options Health Research, LLC, Tulsa, OK, USA, <sup>7</sup>CHU Henri Mondor, CRETEIL, France, <sup>8</sup>Yale University School of Medicine, New Haven, CT, USA, <sup>9</sup>Hopitale Adultes de Braboios, Vandoeuvre les Nancy, France, <sup>10</sup>Alabama Liver & Digestive Specialists, Montgomery, AL, <sup>11</sup>James J Peters VAMC, Bronx, NY, <sup>12</sup>Healthcare Research Consultants, Tulsa, OK, <sup>13</sup>Mercy Medical Center, Baltimore, MD, <sup>14</sup>Carolinas Center for Liver Disease Research Dept, Statesville, NC, <sup>15</sup>Bristol Meyer Squibb Co., Wallingford, CT, USA. *stanislas.pol@cch.aphp.fr</em></td><td valign=top><em>1373 </td></tr> <tr> <td><a href='Abstract14.htm'><B>LYMPHOCYTE-HEPATOCYTE INTERACTIONS: HEPATITIS C VIRUS CHANGES THE RULES</B></a> </em><br> <b>Z. Stamataki</b><sup>1</sup>*, O.S. Qureshi<sup>1</sup>, G.M. Reynolds<sup>2</sup>, C. Mee<sup>1</sup>, P. Maurel<sup>3</sup>, L. Hibbert<sup>4</sup>, J.A. Waters<sup>4</sup>, G.R. Foster<sup>4</sup>, J.Z. Rappoport<sup>5</sup>, S.G. Hübscher<sup>6</sup>, D.H. Adams<sup>2</sup>, J.A. McKeating<sup>1</sup><br> <em><sup>1</sup>MRC Centre for Immune Regulation, University of Birmingham, <sup>2</sup>Centre for Liver Research, NIHR Biomedical Research Unit, University of Birmingham, Birmingham, UK, <sup>3</sup>Hepatic Stem Cells and Liver Biotherapy, Inserm U1040, IRB, CHRU Saint Eloi, Montpellier, France, <sup>4</sup>The Liver Unit, Queen Mary University of London, London, <sup>5</sup>School of Biosciences, University of Birmingham, <sup>6</sup>Department of Cellular Pathology, Queen Elizabeth Hospital Birmingham, Birmingham, UK. *z.stamataki@bham.ac.uk</em></td><td valign=top><em>1374 </td></tr> <tr> <td><a href='Abstract13.htm'><B>SPLEEN STIFFNESS MEASUREMENT USING FIBROSCAN AND A MODIFIED CALCULATION ALGORITHM INCREASES THE DIAGNOSIS PERFORMANCE OF LARGE ESOPHAGEAL VARICES IN CIRRHOTIC PATIENTS</B></a> </em><br> <b>H. Stefanescu</b><sup>1</sup>*, C. Bastard<sup>2</sup>, M. Lupsor<sup>1</sup>, D. Feier<sup>1</sup>, V. Miette<sup>2</sup>, L. Sandrin<sup>2</sup>, R. Badea<sup>1</sup><br> <em><sup>1</sup>3rd Medical Clinic, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania, <sup>2</sup>Echosens, Paris, France. *hstefanescu@umfcluj.ro</em></td><td valign=top><em>1375 </td></tr> <tr> <td><a href='Abstract6.htm'><B><B>THE ASPIRE TRIAL: TMC435 IN TREATMENT-EXPERIENCED PATIENTS WITH GENOTYPE-1 HCV INFECTION WHO HAVE FAILED PREVIOUS PEGIFN/RBV TREATMENT</B></B></a> </em><br> <b>S. Zeuzem</b><sup>1</sup>*, G.R. Foster<sup>2</sup>, M.W. Fried<sup>3</sup>, C. Hezode<sup>4</sup>, G.M. Hirschfield<sup>5</sup>, I. Nikitin<sup>6</sup>, F. Poordad<sup>7</sup>, O. Lenz<sup>8</sup>, M. Peeters<sup>8</sup>, V. Sekar<sup>9</sup>, G. De Smedt<sup>8</sup><br> <em><sup>1</sup>J.W. Goethe University Hospital, Frankfurt, Germany, <sup>2</sup>Queen Marys University of London, London, UK, <sup>3</sup>University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, <sup>4</sup>Hôpital Henri-Mondor, Université Paris-Est Créteil, Créteil, France, <sup>5</sup>Toronto Western Hospital Liver Centre, Toronto, ON, Canada, <sup>6</sup>Russian State Medical University, Moscow, Russia, <sup>7</sup>Cedars-Sinai Medical Center, Los Angeles, CA, USA, <sup>8</sup>Tibotec BVBA, Mechelen, Belgium, <sup>9</sup>Tibotec Inc, Yardley, PA, USA. *zeuzem@em.uni-frankfurt.de</em></td><td valign=top><em>1376 </td></tr> </table><a href='index.asp'>Back</a><br> <p>&nbsp;</p> <p>&nbsp;</p></td> </tr> </table> </body> </html>